Dermagraft deal extended to venous applications
This article was originally published in Clinica
Advanced Tissue Sciences and Smith & Nephew have expanded their 50:50 joint venture to include the development and marketing of Dermagraft for venous ulcers, pressure sores, burns and other wounds. The new agreement is valid worldwide except for the US and also covers the marketing of Dermagraft TC, a temporary covering for partial and full-thickness burns.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.